Experience:
5+ years of experience
Concerned about your lack of experience? Learn More...
Employment Type:
Full time
Posted:
4/6/2017
Job Category:
Research
See more jobs for students and recent grads who studied:
Associate Scientist II, ALS Target Validation Research
Biogen | Cambridge, Massachusetts
Tell Us More About Your Job Preferences
By telling us what you think of this job, we can help find jobs that match your interests. If you want to see more jobs like this, click on the smiley face. Or if this job isn't what you are looking for, click the frowny face. Learn More...

Follow This Company
Share

Job Description

External Posting TitleAssociate Scientist II, ALS Target Validation Research
Job DescriptionThe Department of Neurology Research is seeking a highly talented and enthusiastic associate to join an in vitro / in vivo target discovery and validation effort in Amyotrophic Lateral Sclerosis (ALS) aimed at bringing new targets and therapeutic strategies from discovery to development. The successful candidate will be expected to support efforts to develop and validate new in vitro ALS models for candidate identification and validate findings in primary mouse tissue.
The successful candidate must have a MS in the Biological Sciences, and will be charged with developing high content assays that will be used to validate genes and pathways identified in genetic screens that affect neurodegeneration. The ideal candidate will have previous experience using cell based methods to investigate neurodegeneration. Experience with biochemical analytical methods such as gel electrophoresis, Western blot, ELISA-type assays, qRT-PCR, as well as immunohistochemistry and immunofluorescence on cells and tissues is important. The candidate will also need experience using AAV or lenti viral transduction approaches as well as experience with RNAi technologies. It is strongly desirable that the candidate has experience basic mouse handling experience with basic surgical techniques. Very strong communication skills are critical for the position as is the ability to work effectively in a highly collaborative research environment.
LocationCambridge, MA, US
Job CategoryResearch
Requisition Number30776BR
QualificationsQualifications

•Must possess significant experience in mammalian cell culture techniques; preferentially also in culturing primary neuronal cells, viral transductions and RNAi delivery.

•Possess significant experience in immunohistological techniques, including tissue processing and sectioning, immunostaining, microscopy techniques and image analysis.

•Possess significant experience in a variety of biochemical analytical methods, including gel electrophoresis, Western blot, ELISA, protein extraction and qRT-PCR.

•Basic experience in rodent-handling, including excellent surgical skills (stereotaxic injections), experience with handling, dosing of rodents, and collecting tissues (brain) and fluids (CSF, plasma).

•Experience developing novel cell-based assays (e.g. microfluidics), functional endpoints and high-content screening (preferred).

•Strong interpersonal and organizational skills, including patience and steady commitment towards achievement of set goals and capacity to maintain detailed written records of research (required).

•Keen knowledge of independent experimental design, underlying scientific principles, and the ability to analyze and assess results.

•Understanding of basic neurobiology of neurodegenerative diseases and mechanisms of neurodegeneration is preferred.
Education
•MS in biological sciences and minimal 5 years of relevant experience in academia or industry
About BiogenThrough cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy and is at the forefront of neurology research for conditions including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics.

With more than 7,000 people worldwide, Biogen is truly a global organization. We are headquartered in Cambridge, Massachusetts, which is home to our research operations. Our international operations are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. With a strong affiliate presence and a network of distribution partners, Biogen has established a global footprint that allows us to capture the greatest value for the products we develop.

All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States.

Please be advised that all legitimate correspondence from a Biogen employee will come from "@biogen.com" email accounts.

About Biogen

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company's products address diseases such as multiple sclerosis, lymphoma and rheumatoid arthritis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is used in the treatment of relapsed or refractory low-grade or follicular, CD20-positive, and B-cell, non-Hodgkin's lymphomas (B-cell NHLs). TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. It also has product candidates, such as BG-12 (acquired with the purchase of Fumapharm), ANTI-CD80 antibody/(galiximab), ANTI-CD23 antibody/(lumiliximab), Ocrelizumab/(Humanized ANTI-CD20 Antibody) and Lixivaptan.In January 2007, the Company completed the acquisition of Syntonix Pharmaceuticals, Inc. (Source: 10-K)

This company profile was created by AfterCollege and is about Biogen. This page is not endorsed by or affiliated with Biogen. For questions regarding company profiles, please email: care@aftercollege.com.